Unicycive Therapeutics Inc (UNCY)

$5.63 +0.06 (1.08%)
Market Cap 155.15M
Revenue (ttm) 0.00
Net Income (ttm) -26.56M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 738,800
Avg Vol 1,709,354
Day's Range N/A - N/A
Shares Out 27.86M
Stochastic %K 76%
Beta 1.79
Analysts Strong Sell
Price Target $28.00

Company Profile

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I cl...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 351 4495
Address:
1975 West El Camino Real, Suite 204, Mountain View, United States
chole1
chole1 Aug. 19 at 7:38 AM
$UNCY How do we know/learn that FDA finally is visiting Shilpa?! Can we assume if UNCY files for a third time, that the inspection has happened for good and not is only scheduled and not happening as last time?
1 · Reply
BLtheKid
BLtheKid Aug. 18 at 5:46 PM
$UNCY I think MM are playing games trying to accumulate everything they can down here and are trying not to let the stock go anywhere unless buyers force it higher. Decent volume early to take it to the high of the day but did not take as much to bring it back down, that's MM playing games because there isn't going to be a constant bid (or ask) of any size most of the time.
0 · Reply
shahidattar
shahidattar Aug. 18 at 5:13 PM
$UNCY can you go to 5.95 today? Please
1 · Reply
Merlintrader
Merlintrader Aug. 18 at 3:24 PM
$UNCY reported a second-quarter net loss of 1.7 million dollars, but that number is flattered by a 7.98 million non-cash gain on the warrant liability. The operating loss was 10.1 million. Cash was 61.4 million at June 30 with runway guided into 2027, and the FDA has now assigned a facility inspection to the third-party manufacturer behind both CRLs. Free Biotech Catalyst Calendar on Merlintrader. https://www.merlintrader.com/unicycive-therapeutics-stock-hub/
0 · Reply
900fix
900fix Aug. 18 at 2:53 PM
$UNCY Who said Gupta will have this taken care of this year? 2 months and nothing. Gupta is incompetent. This goes well into 27.
2 · Reply
taki
taki Aug. 18 at 10:15 AM
$UNCY Despite the lack of approval, Unicycive is already preparing for a potential market launch. This includes: Market access preparations Reimbursement strategy Patient support program 'UniSource' Building market awareness among nephrologists and dialysis centers Management is signaling that they still expect approval. https://ir.unicycive.com/news/detail/124/unicycive-therapeutics-announces-second-quarter-2026
0 · Reply
Gebinator
Gebinator Aug. 18 at 5:02 AM
$ARDX wouldn't it be wild if Foster's new gig with a pre-commercial biotech was at $UNCY?
1 · Reply
erictwin1
erictwin1 Aug. 17 at 2:56 AM
$UNCY Come clean you scum bags, oh think you wont end op in jail for securities fraud clown
3 · Reply
erictwin1
erictwin1 Aug. 17 at 2:54 AM
$UNCY one more month and i will get in touch with every lawer in town
1 · Reply
erictwin1
erictwin1 Aug. 17 at 2:51 AM
$UNCY Just wondering why no news from uncy staff about anything, Did they possibly Fuck againa and know that everyone of us will sell everthing and bury this gupta creature
0 · Reply
Latest News on UNCY
Unicycive Therapeutics reports Q2 EPS (6c), consensus (33c)

2026-08-17T09:49:42.000Z - 2 days ago

Unicycive Therapeutics reports Q2 EPS (6c), consensus (33c)

Unicycive Therapeutics price target lowered to $20 from $22 at B. Riley

2026-08-17T09:06:14.000Z - 2 days ago

Unicycive Therapeutics price target lowered to $20 from $22 at B. Riley

Unicycive Therapeutics price target lowered to $25 from $37 at Guggenheim

2026-08-17T08:13:24.000Z - 2 days ago

Unicycive Therapeutics price target lowered to $25 from $37 at Guggenheim

Unicycive Therapeutics price target lowered to $20 from $22 at B. Riley

2026-08-17T07:39:55.000Z - 2 days ago

Unicycive Therapeutics price target lowered to $20 from $22 at B. Riley

Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update

Aug 12, 2026, 7:19 AM EDT - 7 days ago

Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update

Unicycive Therapeutics Quarterly report: Q2 2026

Aug 12, 2026, 7:00 AM EDT - 7 days ago

Unicycive Therapeutics Quarterly report: Q2 2026

Unicycive Therapeutics Earnings release: Q2 2026

Aug 12, 2026, 7:00 AM EDT - 7 days ago

Unicycive Therapeutics Earnings release: Q2 2026

Unicycive Therapeutics Slides: Corporate presentation

Jul 31, 2026, 7:00 AM EDT - 19 days ago

Unicycive Therapeutics Slides: Corporate presentation

Unicycive Therapeutics price target lowered to $50 from $60 at Noble Capital

2026-07-01T13:45:11.000Z - 6 weeks ago

Unicycive Therapeutics price target lowered to $50 from $60 at Noble Capital

Unicycive Therapeutics price target lowered to $13 from $18 at Benchmark

2026-07-01T12:50:20.000Z - 6 weeks ago

Unicycive Therapeutics price target lowered to $13 from $18 at Benchmark

Johnson Fistel Investigates Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on Behalf of Investors

Jun 30, 2026, 12:51 PM EDT - 7 weeks ago

Johnson Fistel Investigates Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on Behalf of Investors

Unicycive Therapeutics price target lowered to $15 from $22 at H.C. Wainwright

2026-06-30T16:35:10.000Z - 7 weeks ago

Unicycive Therapeutics price target lowered to $15 from $22 at H.C. Wainwright

Unicycive Therapeutics CRL tied to same vendor deficiency, says B. Riley

2026-06-30T14:50:20.000Z - 7 weeks ago

Unicycive Therapeutics CRL tied to same vendor deficiency, says B. Riley

Unicycive Therapeutics receives complete response letter from FDA for OLC NDA

2026-06-30T11:25:41.000Z - 7 weeks ago

Unicycive Therapeutics receives complete response letter from FDA for OLC NDA

Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)

Jun 30, 2026, 7:05 AM EDT - 7 weeks ago

Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)

Unicycive Therapeutics Proxy statement: Proxy filing

Jun 22, 2026, 8:00 AM EDT - 2 months ago

Unicycive Therapeutics Proxy statement: Proxy filing

Unicycive Therapeutics files $150M mixed securities shelf

2026-06-05T20:20:10.000Z - 2 months ago

Unicycive Therapeutics files $150M mixed securities shelf

Unicycive Therapeutics Registration statement: Registration filing

Jun 5, 2026, 8:00 AM EDT - 2 months ago

Unicycive Therapeutics Registration statement: Registration filing

Unicycive Therapeutics Slides: Corporate presentation

Jun 4, 2026, 7:00 AM EDT - 2 months ago

Unicycive Therapeutics Slides: Corporate presentation

Unicycive Therapeutics price target raised to $18 from $15 at Benchmark

2026-06-02T13:07:41.000Z - 2 months ago

Unicycive Therapeutics price target raised to $18 from $15 at Benchmark

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:27 AM EDT - 2 months ago

Unicycive Therapeutics Earnings release

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:27 AM EDT - 2 months ago

Unicycive Therapeutics Earnings release

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:26 AM EDT - 2 months ago

Unicycive Therapeutics Earnings release

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:26 AM EDT - 2 months ago

Unicycive Therapeutics Earnings release

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:26 AM EDT - 2 months ago

Unicycive Therapeutics Earnings release

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:25 AM EDT - 2 months ago

Unicycive Therapeutics Earnings release

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:25 AM EDT - 2 months ago

Unicycive Therapeutics Earnings release

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:25 AM EDT - 2 months ago

Unicycive Therapeutics Earnings release

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:24 AM EDT - 2 months ago

Unicycive Therapeutics Earnings release

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:24 AM EDT - 2 months ago

Unicycive Therapeutics Earnings release

Unicycive Therapeutics management to meet virtually with Piper Sandler

2026-05-28T15:05:39.000Z - 2 months ago

Unicycive Therapeutics management to meet virtually with Piper Sandler

Unicycive Therapeutics price target lowered to $37 from $40 at Guggenheim

2026-05-13T11:14:54.000Z - 3 months ago

Unicycive Therapeutics price target lowered to $37 from $40 at Guggenheim

Unicycive Therapeutics Slides: Company presentation

May 13, 2026, 7:00 AM EDT - 3 months ago

Unicycive Therapeutics Slides: Company presentation

Unicycive Therapeutics reports Q1 EPS (50c), consensus (47c)

2026-05-12T11:51:45.000Z - 3 months ago

Unicycive Therapeutics reports Q1 EPS (50c), consensus (47c)

Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

May 12, 2026, 7:05 AM EDT - 3 months ago

Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

Unicycive Therapeutics initiated with a Buy at B. Riley

2026-05-01T14:07:09.000Z - 3 months ago

Unicycive Therapeutics initiated with a Buy at B. Riley

Unicycive Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 15, 2026, 3:45 PM EDT - 4 months ago

Unicycive Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference

Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Apr 9, 2026, 7:05 AM EDT - 4 months ago

Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Unicycive Therapeutics price target lowered to $15 from $21 at Benchmark

2026-04-06T11:30:08.000Z - 4 months ago

Unicycive Therapeutics price target lowered to $15 from $21 at Benchmark

Unicycive Therapeutics price target lowered to $40 from $46 at Guggenheim

2026-04-02T10:59:29.000Z - 4 months ago

Unicycive Therapeutics price target lowered to $40 from $46 at Guggenheim

Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update

Mar 30, 2026, 7:05 AM EDT - 5 months ago

Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update

Important Notice to Long-Term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf

Feb 17, 2026, 9:15 AM EST - 6 months ago

Important Notice to Long-Term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf

Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim's Emerging Outlook: Biotech Summit

Feb 4, 2026, 7:05 AM EST - 7 months ago

Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim's Emerging Outlook: Biotech Summit

UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission

Jan 29, 2026, 9:15 AM EST - 7 months ago

UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission

Jan 29, 2026, 7:05 AM EST - 7 months ago

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission

Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC)

Dec 29, 2025, 7:05 AM EST - 8 months ago

Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC)

Important Notice to Long-term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf

Dec 1, 2025, 1:41 PM EST - 9 months ago

Important Notice to Long-term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf

Unicycive Therapeutics to Participate in Upcoming Investor Events in December

Nov 25, 2025, 7:05 AM EST - 9 months ago

Unicycive Therapeutics to Participate in Upcoming Investor Events in December

Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

Nov 12, 2025, 7:05 AM EST - 10 months ago

Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

Unicycive Therapeutics to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

Nov 3, 2025, 7:05 AM EST - 10 months ago

Unicycive Therapeutics to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

Unicycive Therapeutics Announces Upcoming Presentation of New Data Reinforcing the Potential of Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia at the American Society of Nephrology Kidney Week 2025 Conference

Oct 30, 2025, 7:05 AM EDT - 10 months ago

Unicycive Therapeutics Announces Upcoming Presentation of New Data Reinforcing the Potential of Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia at the American Society of Nephrology Kidney Week 2025 Conference

Unicycive Therapeutics Provides Update from FDA Type A Meeting and Expects to Resubmit OLC NDA Before Year-End

Oct 28, 2025, 7:05 AM EDT - 10 months ago

Unicycive Therapeutics Provides Update from FDA Type A Meeting and Expects to Resubmit OLC NDA Before Year-End

Unicycive Therapeutics to Participate in Upcoming Investor Events in September

Aug 26, 2025, 7:00 AM EDT - 1 year ago

Unicycive Therapeutics to Participate in Upcoming Investor Events in September

chole1
chole1 Aug. 19 at 7:38 AM
$UNCY How do we know/learn that FDA finally is visiting Shilpa?! Can we assume if UNCY files for a third time, that the inspection has happened for good and not is only scheduled and not happening as last time?
1 · Reply
BLtheKid
BLtheKid Aug. 18 at 5:46 PM
$UNCY I think MM are playing games trying to accumulate everything they can down here and are trying not to let the stock go anywhere unless buyers force it higher. Decent volume early to take it to the high of the day but did not take as much to bring it back down, that's MM playing games because there isn't going to be a constant bid (or ask) of any size most of the time.
0 · Reply
shahidattar
shahidattar Aug. 18 at 5:13 PM
$UNCY can you go to 5.95 today? Please
1 · Reply
Merlintrader
Merlintrader Aug. 18 at 3:24 PM
$UNCY reported a second-quarter net loss of 1.7 million dollars, but that number is flattered by a 7.98 million non-cash gain on the warrant liability. The operating loss was 10.1 million. Cash was 61.4 million at June 30 with runway guided into 2027, and the FDA has now assigned a facility inspection to the third-party manufacturer behind both CRLs. Free Biotech Catalyst Calendar on Merlintrader. https://www.merlintrader.com/unicycive-therapeutics-stock-hub/
0 · Reply
900fix
900fix Aug. 18 at 2:53 PM
$UNCY Who said Gupta will have this taken care of this year? 2 months and nothing. Gupta is incompetent. This goes well into 27.
2 · Reply
taki
taki Aug. 18 at 10:15 AM
$UNCY Despite the lack of approval, Unicycive is already preparing for a potential market launch. This includes: Market access preparations Reimbursement strategy Patient support program 'UniSource' Building market awareness among nephrologists and dialysis centers Management is signaling that they still expect approval. https://ir.unicycive.com/news/detail/124/unicycive-therapeutics-announces-second-quarter-2026
0 · Reply
Gebinator
Gebinator Aug. 18 at 5:02 AM
$ARDX wouldn't it be wild if Foster's new gig with a pre-commercial biotech was at $UNCY?
1 · Reply
erictwin1
erictwin1 Aug. 17 at 2:56 AM
$UNCY Come clean you scum bags, oh think you wont end op in jail for securities fraud clown
3 · Reply
erictwin1
erictwin1 Aug. 17 at 2:54 AM
$UNCY one more month and i will get in touch with every lawer in town
1 · Reply
erictwin1
erictwin1 Aug. 17 at 2:51 AM
$UNCY Just wondering why no news from uncy staff about anything, Did they possibly Fuck againa and know that everyone of us will sell everthing and bury this gupta creature
0 · Reply
Logmart939
Logmart939 Aug. 16 at 11:05 PM
$UNCY let’s have another great week and get approval before end of year!
0 · Reply
erictwin1
erictwin1 Aug. 16 at 8:58 PM
$UNCY Is anyone adding shares tmrw???
1 · Reply
bpm78
bpm78 Aug. 14 at 11:20 PM
$UNCY been trying to estimate timeline and the word "assigned" seemed interesting. There is FDA documentation that confirms “assigned” and “scheduled” are distinct stages. That probably makes UNCY's wording quite important. Inspection need identified → inspection assignment initiated → ORA schedules inspection → inspection conducted → report/classification. There is other guidance that fda informs applicant within 60d. But that is applicable to original applications. We are beyond that now so hopefully they schedule more timely. Hopefully get scheduled and completed by end of September. Allow 30d for feedback and resubmission....end of October. Wish for class 1....end of December. Assumes clean inspection. Possible? Glta.
1 · Reply
Orlandotrader
Orlandotrader Aug. 14 at 3:45 PM
$UNCY Smart money knows that FDA finally set an inspection date. Hope for 2 Month Review. FDA owns us that for the Inspection delay!!!!
0 · Reply
erictwin1
erictwin1 Aug. 13 at 8:49 PM
$UNCY People people people, just add more shares and you will be rreardrd eventually.
3 · Reply
buymoremakemore
buymoremakemore Aug. 13 at 7:54 PM
$UNCY Nice recovery here
1 · Reply
Logmart939
Logmart939 Aug. 13 at 6:56 PM
$UNCY not loving the all the price target cuts from analysts.
2 · Reply
StochAlpha
StochAlpha Aug. 13 at 6:39 PM
$UNCY Unicycive Therapeutics Announces Q2 Results and Provides Business Update. - Company expects to resubmit New Drug Application (NDA) for oxylanthanum carbonate (OLC) assuming completion of successful inspection of third-party manufacturing vendor - FDA has assigned a facility inspection to third-party manufacturing vendor of OLC - As of June 30, 2026, unaudited cash, cash equivalents, and marketable securities totaled $61.4 million, with expected runway into 2027 https://ir.unicycive.com/news/detail/124/unicycive-therapeutics-announces-second-quarter-2026
1 · Reply
Avatar23
Avatar23 Aug. 13 at 4:26 PM
$UNCY MAJOR Assumption: Inspection Sept. 1–4 → good outcome/no form 483→ resubmit NDA Sept. 10–18 → Class 1 goal date roughly Nov. 10–18.
1 · Reply
BLtheKid
BLtheKid Aug. 13 at 4:02 PM
$UNCY looks like yesterday it was all about MM "making" a market. ginned up the price when a little buying came in off the hop and kept it up there as they kept exciting more buyers in. a day later, a drop on no volume as they'll slowly buy back what they sold yesterday. was mystified when it moved yesterday, they just said the same thing four analysts already told us six weeks ago. with the add-on the inspection has actually been scheduled. on the other hand, I've never understood why the price isn't higher to begin with, maybe high 5's or even into the 6's.
0 · Reply
Legendary_Scoober
Legendary_Scoober Aug. 13 at 3:52 PM
$UNCY don’t tell me that was all the green we’re going to get.
0 · Reply
RunningRobert1
RunningRobert1 Aug. 13 at 2:07 PM
$UNCY Unicycive Therapeutics UNCY Q2 2026 Summary 13Aug2026 https://youtu.be/IwmXdHsLelQ Steady as we go, really we are just waiting for a PR for the inspection of the CMO, then we will go from there!
1 · Reply